Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS Class-Action Lawsuit Against Celgene Is First By Patients

Executive Summary

Patients For Affordable Drugs Founder David Mitchell alleges Celgene's unlawful delay tactics like REMS obstruction kept generic versions of Thalomid and Revlimid off the market, forcing plaintiffs to pay higher costs.


Related Content

REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
US Patent Battles May Resume Next Congress; Reps Press For IPR Reform
Natco Doubles Down On US With Ambitious ANDA Plan
FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene
Generic Companies Gain Little From FDA Decision On Access To REMS Drugs
The Impact of REMS on Generic Drug Approvals and Drug Competition


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts